Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Health & Biotech
ASX Quarterly Health Wrap: Which companies are making progress in clinical trials?
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Israel’s strikes grip markets; oil and gold spike while the ASX tumbles over 1pc
Health & Biotech
Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial
Health & Biotech
ASX Health Stocks: Paradigm responds to US FDA, seeks marketing approval from TGA
News
Market Highlights: Netflix shares dumped, Bitcoin halving looms, and 5 ASX small caps to watch today
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 3
Stockhead TV
What’s in store for 2024: Paradigm Biopharmaceuticals
Health & Biotech
ASX stocks striving to inject youthfulness into an aging world population
Health & Biotech
ASX Health Stocks: Paradigm takes another step forward as Phase 2 trial meets primary endpoint
News
ASX Small Caps Lunch Wrap: Are tomatoes about to push Spain and France to the brink of war?
News
ASX Quarterly Wrap: HTG sales momentum continues, Race Oncology appoints CEO
News
ASX Small Caps Lunch Wrap: Who’s come up with a brutal way to get back at your ex on Valentine’s Day?
Health & Biotech
ASX biotechs with big catalysts in 2024: Part 2
Health & Biotech